Animals
Brain
/ diagnostic imaging
Clozapine
/ chemistry
Contrast Media
/ chemistry
Diagnostic Techniques, Radioisotope
Fluorine Radioisotopes
/ chemistry
Halogenation
Humans
Mice, Transgenic
Models, Animal
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ chemistry
Structure-Activity Relationship
(18)F
Chemogenetics
DREADD
PET
SAR
hM3Dq
hM4Di
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Mar 2021
05 Mar 2021
Historique:
received:
30
08
2020
revised:
08
11
2020
accepted:
21
11
2020
pubmed:
8
12
2020
medline:
1
5
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Designer Receptors Exclusively Activated by Designer Drugs (DREADD) are a preclinical chemogenetic approach with clinical potential for various disorders. In vivo visualization of DREADDs has been achieved with positron emission tomography (PET) using
Identifiants
pubmed: 33280897
pii: S0223-5234(20)31019-9
doi: 10.1016/j.ejmech.2020.113047
pmc: PMC7925357
mid: NIHMS1649716
pii:
doi:
Substances chimiques
Contrast Media
0
Fluorine Radioisotopes
0
Radiopharmaceuticals
0
Fluorine-18
GZ5I74KB8G
Clozapine
J60AR2IKIC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113047Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB024495
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG054802
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG054802
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest FH, JB, MGP, MM and AGH are co-inventors on a U.S. patent covering PET imaging with [(18)F]7b and as such are entitled to a portion of any licensing fees and royalties generated by this technology.
Références
Nature. 2016 May 18;534(7607):369-73
pubmed: 27281221
Nat Commun. 2016 Dec 06;7:13605
pubmed: 27922009
Psychopharmacology (Berl). 1989;99(1):8-12
pubmed: 2528781
Curr Pharm Des. 2006;12(30):3877-900
pubmed: 17073685
Science. 2017 Aug 4;357(6350):503-507
pubmed: 28774929
J Clin Psychiatry. 1994 Sep;55 Suppl B:47-52
pubmed: 7961573
J Med Chem. 1997 Dec 5;40(25):4146-53
pubmed: 9406603
Neuron. 2016 Feb 17;89(4):683-94
pubmed: 26889809
J Nucl Med. 2012 May;53(5):805-12
pubmed: 22492734
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):867-71
pubmed: 19389456
J Clin Invest. 2017 Feb 1;127(2):720-734
pubmed: 28112685
J Nucl Med. 1996 Mar;37(3):513-20
pubmed: 8772658
Psychopharmacology (Berl). 1986;89(2):248-52
pubmed: 3088645
Angew Chem Int Ed Engl. 2019 Feb 25;58(9):2580-2605
pubmed: 30054961
J Nucl Med. 1979 Apr;20(4):350-7
pubmed: 43884
Mol Imaging Biol. 2003 Nov-Dec;5(6):376-89
pubmed: 14667492
ACS Chem Neurosci. 2015 Mar 18;6(3):476-84
pubmed: 25587888
Chem Rev. 2016 Jan 27;116(2):719-66
pubmed: 26751274
Bioorg Med Chem Lett. 2006 Sep 1;16(17):4543-7
pubmed: 16809034
Neuron. 2009 Jul 16;63(1):27-39
pubmed: 19607790
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8
pubmed: 17360345
EBioMedicine. 2019 May;43:641-649
pubmed: 31078519
Nat Commun. 2019 Oct 11;10(1):4627
pubmed: 31604917
J Neurosci. 2016 Nov 9;36(45):11544-11558
pubmed: 27911758
Sci Rep. 2016 Aug 03;6:30570
pubmed: 27484850
ACS Chem Neurosci. 2014 Jan 15;5(1):24-9
pubmed: 24219174
Science. 2007 Sep 28;317(5846):1881-6
pubmed: 17901324
Nat Neurosci. 2020 Sep;23(9):1157-1167
pubmed: 32632286